Inventiva S.A. (IVEVF)
PNK · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Peers in Healthcare
Inventiva S.A. has no peer companies in this window.
Recent press releases
April 2026
Inventiva Retools Leadership Ahead of Phase 3 Drug Trial Data
# 🧾 What This Document Is This is a **6-K filing**, which is a report foreign companies (like French-based Inventiva) submit to the SEC to announce major news. This specific filing contains a press release. Think of it as an official, legally required announcement to investors about a significant c
March 2026
Inventiva S.A. — 6-K Filing
# 🔍 What This Document Is This is a **Form 6-K** filing from Inventiva, a French-American biotech company. It's essentially their **2025 annual report** wrapped in a press release, giving investors a full business and financial update. It explains how they spent their money, what progress they mad
SEC filings
All filings →Insider trades
All insider trades →Inventiva S.A. has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at Inventiva S.A.
All people →No officers or directors have been indexed for Inventiva S.A..